235 related articles for article (PubMed ID: 35410851)
1. Clinical update on risks and efficacy of anti-SARS-CoV-2 vaccines in patients with autoimmune hepatitis and summary of reports on post-vaccination liver injury.
Lleo A; Cazzagon N; Rigamonti C; Cabibbo G; Lai Q; Muratori L; Carbone M;
Dig Liver Dis; 2022 Jun; 54(6):722-726. PubMed ID: 35410851
[TBL] [Abstract][Full Text] [Related]
2. Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients.
Murray SM; Pose E; Wittner M; Londoño MC; Schaub G; Cook J; Dimitriadis S; Meacham G; Irwin S; Lim Z; Duengelhoef P; Sterneck M; Lohse AW; Perez V; Trivedi P; Bhandal K; Mullish BH; Manousou P; Provine NM; Avitabile E; Carroll M; Tipton T; Healy S; Burra P; Klenerman P; Dunachie S; Kronsteiner B; Maciola AK; Pasqual G; Hernandez-Gea V; Garcia-Pagan JC; Lampertico P; Iavarone M; Gines P; Lütgehetmann M; Schulze Zur Wiesch J; Russo FP; Barnes E; Marjot T;
J Hepatol; 2024 Jan; 80(1):109-123. PubMed ID: 37863203
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease.
Duengelhoef P; Hartl J; Rüther D; Steinmann S; Brehm TT; Weltzsch JP; Glaser F; Schaub GM; Sterneck M; Sebode M; Weiler-Normann C; Addo MM; Lütgehetmann M; Haag F; Schramm C; Schulze Zur Wiesch J; Lohse AW
United European Gastroenterol J; 2022 Apr; 10(3):319-329. PubMed ID: 35289983
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune liver diseases and SARS-CoV-2.
Sgamato C; Rocco A; Compare D; Minieri S; Marchitto SA; Maurea S; Nardone G
World J Gastroenterol; 2023 Mar; 29(12):1838-1851. PubMed ID: 37032727
[TBL] [Abstract][Full Text] [Related]
5. Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics.
Uzun S; Zinner CP; Beenen AC; Alborelli I; Bartoszek EM; Yeung J; Calgua B; Reinscheid M; Bronsert P; Stalder AK; Haslbauer JD; Vosbeck J; Mazzucchelli L; Hoffmann T; Terracciano LM; Hutter G; Manz M; Panne I; Boettler T; Hofmann M; Bengsch B; Heim MH; Bernsmeier C; Jiang S; Tzankov A; Terziroli Beretta-Piccoli B; Matter MS
J Hepatol; 2023 Sep; 79(3):666-676. PubMed ID: 37290592
[TBL] [Abstract][Full Text] [Related]
6. First report of post-transplant autoimmune hepatitis recurrence following SARS-CoV-2 mRNA vaccination.
Mahalingham A; Duckworth A; Griffiths WJH
Transpl Immunol; 2022 Jun; 72():101600. PubMed ID: 35390478
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune Hepatitis Following Vaccination for SARS-CoV-2 in Korea: Coincidence or Autoimmunity?
Kang SH; Kim MY; Cho MY; Baik SK
J Korean Med Sci; 2022 Apr; 37(15):e116. PubMed ID: 35437965
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune hepatitis after COVID-19 vaccination.
Zheng H; Zhang T; Xu Y; Lu X; Sang X
Front Immunol; 2022; 13():1035073. PubMed ID: 36505482
[TBL] [Abstract][Full Text] [Related]
9. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
Thuluvath PJ; Robarts P; Chauhan M
J Hepatol; 2021 Dec; 75(6):1434-1439. PubMed ID: 34454993
[TBL] [Abstract][Full Text] [Related]
10. Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: A novel clinical entity?
Ghielmetti M; Schaufelberger HD; Mieli-Vergani G; Cerny A; Dayer E; Vergani D; Terziroli Beretta-Piccoli B
J Autoimmun; 2021 Sep; 123():102706. PubMed ID: 34293683
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination.
Vuille-Lessard É; Montani M; Bosch J; Semmo N
J Autoimmun; 2021 Sep; 123():102710. PubMed ID: 34332438
[TBL] [Abstract][Full Text] [Related]
12. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
Cornberg M; Buti M; Eberhardt CS; Grossi PA; Shouval D
J Hepatol; 2021 Apr; 74(4):944-951. PubMed ID: 33563499
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 vaccine and autoimmune hepatitis.
Sookaromdee P; Wiwanitkit V
Rev Esp Enferm Dig; 2022 Oct; 114(10):631. PubMed ID: 35469403
[TBL] [Abstract][Full Text] [Related]
14. Autoimmune hepatitis after SARS-C¬¬oV-2 vaccination.
Díez Ruiz S; Quiñones Castro R; Alcoba Vega L; Martín Izquierdo A; González Puente I; Rodríguez Martín L; Díez Rodríguez R; Jorquera Plaza F
Rev Esp Enferm Dig; 2023 Jul; 115(7):406. PubMed ID: 37114399
[TBL] [Abstract][Full Text] [Related]
15. Insights into new-onset autoimmune diseases after COVID-19 vaccination.
Guo M; Liu X; Chen X; Li Q
Autoimmun Rev; 2023 Jul; 22(7):103340. PubMed ID: 37075917
[TBL] [Abstract][Full Text] [Related]
16. Histological and serological features of acute liver injury after SARS-CoV-2 vaccination.
Codoni G; Kirchner T; Engel B; Villamil AM; Efe C; Stättermayer AF; Weltzsch JP; Sebode M; Bernsmeier C; Lleo A; Gevers TJ; Kupčinskas L; Castiella A; Pinazo J; De Martin E; Bobis I; Sandahl TD; Pedica F; Invernizzi F; Del Poggio P; Bruns T; Kolev M; Semmo N; Bessone F; Giguet B; Poggi G; Ueno M; Jang H; Elpek GÖ; Soylu NK; Cerny A; Wedemeyer H; Vergani D; Mieli-Vergani G; Lucena MI; Andrade RJ; Zen Y; Taubert R; Terziroli Beretta-Piccoli B
JHEP Rep; 2023 Jan; 5(1):100605. PubMed ID: 36440259
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 infection in patients with autoimmune hepatitis.
Marjot T; Buescher G; Sebode M; Barnes E; Barritt AS; Armstrong MJ; Baldelli L; Kennedy J; Mercer C; Ozga AK; Casar C; Schramm C; ; Moon AM; Webb GJ; Lohse AW
J Hepatol; 2021 Jun; 74(6):1335-1343. PubMed ID: 33508378
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 vaccine, a new autoimmune hepatitis trigger?
López Romero-Salazar F; Veras Lista M; Gómez-Domínguez E; Ibarrola-Andrés C; Muñoz Gómez R; Fernández Vázquez I
Rev Esp Enferm Dig; 2022 Sep; 114(9):567-568. PubMed ID: 35373571
[TBL] [Abstract][Full Text] [Related]
19. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
